Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 28, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Hemophilia B
Interventions
BIOLOGICAL

Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)

Lyophilized powder for solution for intravenous injection

Trial Locations (7)

63000

North China University Of Science And Technology Affiliated Hospital, Tangshan

100045

Beijing Children's Hospital, Beijing

250013

Jinan Central Hospital, Jinan

300020

Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin

350001

Union Hospital Affiliated to Fujian Medical University, Fuzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

550004

Affiliated Hospital of Guizhou Medical University, Guiyang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY